

Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study

Maura Massimino (✉)¹, Marta Podda¹, Lorenza Gandola², Emanuele Pignoli³, Ettore Seregni⁴, Carlo Morosi⁵, Filippo Spreafico¹, Andrea Ferrari¹, Emilia Pecori², Monica Terenziani¹

¹*Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20146, Italy;* ²*Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20146, Italy;* ³*Medical Physics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20146, Italy;* ⁴*Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20146, Italy;* ⁵*Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20146, Italy*

© Higher Education Press 2020

Abstract Primary hypothyroidism commonly occurs after radiotherapy (RT), and coincides with increased circulating thyroid-stimulating hormone (TSH) levels. We tested therefore the protective effect of suppressing TSH with L-thyroxine during RT for medulloblastoma/PNET and Hodgkin lymphoma (HL) in a prospective cohort study. From 1998 to 2001, a total of 37 euthyroid children with medulloblastoma/PNET plus 14 with HL, scheduled for craniospinal irradiation and mediastinum/neck radiotherapy, respectively, underwent thyroid ultrasound and free triiodothyronine (FT3), free thyroxine (FT4), and TSH evaluation at the beginning and end of craniospinal irradiation. From 14 days before and up to the end of radiotherapy, patients were administered L-thyroxine checking every 3 days TSH to ensure a value $< 0.3 \mu\text{IU/mL}$. During follow-up, blood tests and ultrasound were repeated; primary hypothyroidism was considered an increased TSH level greater than normal range. Twenty-two/37 patients with medulloblastoma/PNET and all the 14 patients with HL were alive after a median 231 months from radiotherapy with 7/22 and 8/14 having correctly reached TSH levels $< 0.3 \mu\text{IU/mL}$ and well matched for other variables. Twenty years on, hypothyroidism-free survival rates differed significantly, being $60\% \pm 15\%$ and $15.6\% \pm 8.2\%$ in TSH-suppressed vs. not-TSH suppressed patients, respectively ($P=0.001$). These findings suggest that hypothyroidism could be durably prevented in two populations at risk of late RT sequelae, but it should be confirmed in a larger cohort.

Keywords iatrogenic primary hypothyroidism; late effects of radiotherapy; long-term follow-up; medulloblastoma; Hodgkin lymphoma

Introduction

Primary hypothyroidism is defined as high serum TSH levels with normal (compensated) or reduced (overt) free thyroxine (FT4) levels. It affects more than one in two patients after radiotherapy (RT) to the neck/mediastinum [1]. Central hypothyroidism is defined instead as low FT4 levels with normal or low basal TSH levels.

Thyroid-stimulating hormone (TSH) correlates with plasma FT4, and is a marker of hypothyroidism. Thyroid activity relies on hypothalamic thyrotropin-releasing hormone being secreted into the pituitary gland, where it stimulates TSH secretion [1]. The latter results in thyroid cell hypertrophy and hyperplasia, increased iodine trapping, and thyroid hormone synthesis. TSH production is stimulated by lower endogenous thyroid hormone levels, and inhibited by exogenous thyroid hormone or increased endogenous thyroid hormone synthesis [2].

In 1998 we tested a “protective” pharmacological TSH suppression in patients receiving RT to part or all of the thyroid bed. Most of the patients involved had craniospinal

Received July 12, 2019; accepted January 14, 2020

Correspondence: Maura Massimino,

maura.massimino@istitutotumori.mi.it

RT for medulloblastoma (MBL) or neck/mediastinum RT for Hodgkin lymphoma (HL). After a mean 7–8 years, our promising results were published [3,4]. Now, with a much extended follow-up, the present report sends a strengthened message to pediatric oncologists and radiotherapists. This paper only concerns primary hypothyroidism as our study goal was to preserve thyroid function in the increasingly common case of children, adolescents, and young adults at risk of hypothyroidism after RT involving the thyroid bed.

Patients and methods

Inclusion criteria

Between January 1998 and February 2001 all children in our pediatric unit at Fondazione IRCCS Istituto Nazionale dei Tumori in Milano scheduled for RT if affected by MBL/PNET (classified by the WHO as supratentorial embryonal tumors since 2016 [5]) or by HL if RT would have involved the thyroid bed were proposed to enter this study; consent by parents was obtained.

Methods

The design followed a prospective cohort study. Patients underwent thyroid ultrasound and FT3, FT4, TSH assay. Simulations with computed tomography, and computer-assisted three-dimensional treatment planning with a dose-volume histogram were used to identify thyroid volumes and corresponding RT isodose distributions. From 14 days beforehand and throughout their RT, patients received L-thyroxine in the morning on an empty stomach (half an hour before breakfast), starting with 1–2 $\mu\text{g/kg}$, and adjusting the dose every 3 days to ensure $\text{TSH} < 0.3 \mu\text{IU/mL}$ (the normal ranges changed for TSH from 1998 to 2011, from 0.6 to $0.3 \mu\text{IU/mL}$ and from 4.6 to $4.2 \mu\text{IU/mL}$ for lower and upper level, respectively). The $0.3 \mu\text{IU/mL}$ threshold was chosen pragmatically as just below normal range but not causing hyperthyroidism (as confirmed in later studies [6]), and defined as “mild” TSH suppression [7]. Based on hormone status, L-thyroxine doses were gradually increased to patients’ individual minimum TSH-suppressive dose before starting RT, maintained throughout the treatment, then rapidly tapered off. Patients were followed up for their primary tumor, thyroid function and parenchymal alterations. Blood tests and ultrasound were repeated after 1 year, and at least annually thereafter.

We originally planned to compare our patients with others treated previously without TSH suppression [8] and similar populations reported by the literature [9–11]. At the first assessment after RT, however, a variable adherence to thyroxine treatment enabled us to group our MBL/PNET

and HL patients by their TSH levels 0.3 (TSH-suppressed) or $\geq 0.3 \mu\text{IU/mL}$ (TSH-not-suppressed) during their RT, obtaining four patient cohorts. Only 2 patients were censored and excluded from further analysis on developing central hypothyroidism.

Differences in hypothyroidism-free survival between patients with and without TSH suppression were analyzed using the Kaplan–Meier method [12] and logrank (Mantel–Cox) test was used to calculate P value. Chi-square tests were used to compare the frequency of patients’ characteristics [13]. A $P < 0.05$ was considered statistically significant.

Results

All the patients object of this paper were maintained in active follow-up consisting of clinical examination, thyroid ultrasound, and blood samples for thyroid function tests that were undertaken at our institution or at a facility closer to the patient’s home. Thyroid function testing was repeated every 6 months and thyroid ultrasound examination every other year. Patients were given a brief form documenting clinical history for the radiologist undertaking the ultrasound examination and, whenever possible, subsequent ultrasound examinations were requested at the same facility and with the same operator to limit inter observer variability in sequential assessments.

Twenty-two of the originally 37 treated patients with MBL/PNET [3] and all the 14 with HL [4], alive and in complete remission at the time of writing, had a median post-RT follow-up of 231 (range 213–243) and 232 (range 207–242) months, respectively, and a median 187 months elapsing since their first thyroid function evaluation (range 33–225). Seven of 22 patients with MBL/PNET and 8/14 with HL had received a correct TSH suppression during whole radiotherapy course always maintaining TSH levels $0.3 \mu\text{IU/mL}$. Median value for FT3 during radiotherapy was 8.37 pmol/L (range 6.48 – 10.99 pmol/L), for FT4 it was 26.42 pmol/L (range 12.59 – 49.15 pmol/L) and for TSH $0.16 \mu\text{IU/mL}$ (range 0.05 – $0.28 \mu\text{IU/mL}$). Transient asymptomatic hyperthyroidism was recorded in 3/15 TSH-suppressed patients, and in 1/21 TSH-not-suppressed (P n.s.).

Though numerically small, the MBL/PNET and HL cohorts were still — nearly 20 years on — well matched for gender, age at RT, disease stage, chemotherapy courses, use of high-dose chemotherapy, thyroid bed RT dose, and duration of follow-up, as explained in details by Table 1. Fig. 1 shows patients diagram from diagnosis, through study results and last follow-up of their thyroid function. Detailing sex and age for the whole population, females were 15/36 with 7 in the TSH-suppressed group, and mean age at diagnosis was 11.3 years (range 1–21 years, SD 5.11) for the 36 survivors with 14.6 years for the

Table 1 MBL/PNET and HL cohorts

Patient code	Sex	Diagnosis	Age at diagnosis (year)	Craniospinal and neck/mediastinum doses in Gy	Myeloablative schedule	Adequate TSH suppression	Hypothyroidism	Interval since starting RT (month)	Other endocrine and metabolic problems
3	M	MBL-S	12	39	No	Yes	No	213	Growth hormone (GH), vit D deficiency
5	F	MBL-S	11	39	No	Yes	No	215	GH deficiency, dyslipidemia
11	M	S-PNET-S	18	39	No	Yes	No	239	No
14	F	MBL-S	21	39	Yes	Yes	Yes	214	No
17	M	MBL-S	21	39	No	Yes	No	237	No
19	M	MBL-S	13	39	No	Yes	No	223	No
22	M	MBL-S	15	39	No	Yes	No	227	GH deficiency, dyslipidemia
1	M	MBL-NS	1	20.8	Yes	No	Yes	235	GH deficiency
2	F	MBL-NS	6	31.2	Yes	No	Yes	219	Dyslipidemia, hyperinsulinism, panhypopituitarism, vit D deficiency, liver steatosis
4	M	MBL-NS	8	20.8	No	No	Yes	243	Dyslipidemia, vit D deficiency
6	M	MBL-NS	6	20.8	No	No	Yes	240	No
7	M	MBL-NS	7	31.2	No	No	No	228	GH deficiency
8	F	MBL-NS	16	39	No	No	Yes	213	No
9	M	S-PNET-NS	2	20.8	Yes	No	No	219	Dyslipidemia, hyperinsulinism, liver steatosis, second thyroid tumor
10	M	MBL-NS	18	39	No	No	No	239	GH deficiency
12	F	MBL-NS	7	31.2	No	No	No	238	No
13	F	MBL-NS	4	20.8	No	No	No	241	GH deficiency, vit D deficiency
15	M	MBL-NS	3	31.2	Yes	No	No	232	GH deficiency
16	M	MBL-NS	5	20.8	No	No	Yes	240	GH deficiency
18	M	MBL-NS	8	20.8	No	No	Yes	222	No

(Continued)

Patient code	Sex	Diagnosis	Age at diagnosis (year)	Craniospinal and neck/mediastinum doses in Gy	Myeloablative schedule	Adequate TSH suppression	Hypothyroidism	Interval since starting RT (month)	Other endocrine and metabolic problems
20	F	MBL-NS	10	39	No	No	Yes	222	Dyslipidemia, vit D deficiency
21	M	MBL-NS	10	39	No	No	Yes	230	Dyslipidemia, hyperinsulinism, panhypopituitarism, liver steatosis
23	M	HL-S	12	30	No	Yes	No	212	No
25	F	HL-S	15	25	No	Yes	Yes	238	Dyslipidemia
29	F	HL-S	16	25	No	Yes	No	215	No
30	M	HL-S	9	25	No	Yes	Yes	240	Second thyroid tumor
31	F	HL-S	17	25	No	Yes	No	207	No
33	M	HL-S	10	30	No	Yes	No	212	No
34	F	HL-S	12	30	No	Yes	No	238	No
36	F	HL-S	17	30	No	Yes	No	227	No
24	F	HL-NS	16	25	No	No	Yes	222	No
26	F	HL-NS	13	26	No	No	Yes	238	No
27	M	HL-NS	13	20	No	No	Yes	209	Dyslipidemia
28	M	HL-NS	10	25	No	No	Yes	232	No
32	F	HL-NS	10	25	No	No	Yes	242	Second thyroid tumor
35	M	HL-NS	15	25.2	No	No	Yes	219	Second thyroid tumor

M, male; F, female; MBL/PNET-S, MBL/PNET TSH-suppressed patients; MBL/PNET-NS, MBL/PNET TSH-not-suppressed patients; HL-S, HL TSH-suppressed patients; HL-NS, HL TSH-not-suppressed patients.




Fig. 1 MBL/PNET and HL patients diagram from diagnosis to present status. hypo, hypothyroid patients; euthy, euthyroid patients.




Fig. 2 Hypothyroidism-free survival rates for TSH-suppressed and TSH-not-suppressed patients.

TSH-suppressed group and 8.9 years for the TSH-not-suppressed group.

Hypothyroidism-free survival rates differed at their latest follow-up: in the MBL/PNET cohort, it was $45.7\% \pm 22.4\%$ for the 7 TSH-suppressed patients and $22.5\% \pm 11.3\%$ for the 15 TSH-not-suppressed ($P = 0.08$); in the HL cohort, it was $75\% \pm 15.3\%$ for the 8 TSH-suppressed patients and 0% for the 6 controls ($P = 0.0009$), respectively. Considering the MBL/PNET and HL patients together, the difference was again significant: $60\% \pm 14.8\%$ for the TSH-suppressed and $15.6\% \pm 8.2\%$ for the TSH-not-suppressed ($P = 0.001$) (HR 7.2, range 2.23–23.23) (Fig. 2). In 22/36 patients, primary hypothyroidism developed after a median 33 months (range 6–61). Colloidal cysts and solid nodules occurred in similar proportions in the TSH-suppressed and control patients, with 6 parenchymal alterations (2 cystic

and 4 nodular) in 15 TSH-suppressed patients and 11 (1 cystic and 10 nodular) in 21 TSH-not-suppressed. Four patients (3 TSH-not-suppressed) developed secondary thyroid tumors (papillary carcinoma in two, and well differentiated tumors in two) at 34, 72, 110, and 217 months after starting RT. Other endocrine and metabolic alterations did not differ by TSH suppression status or onset of hypothyroidism (Table 1).

Discussion

Thyroid dysfunction may develop from months to years after RT, even after very small doses only partially involving the gland [8,14,15]. RT almost always causes hypothyroidism, and very rarely leads to hyperthyroidism [8,14–16].

Endocrine disorders negatively affect growth and development in children given lengthy cancer treatments, so modern oncological treatments try to contain the risk of such well-known late sequelae [17]. More than 20 years ago, we tried a cheap and simple approach to protecting our patients against post-RT hypothyroidism involving TSH suppression.

Around the time of our two previous publications [3,4], van Santen *et al.* reported failing to prevent hypothyroidism in an animal model using much the same approach [18]. As van Santen *et al.* themselves suggested, the discrepant results may be largely because TSH was lowered, but not suppressed before RT in their Wistar rats, to avoid causing hyperthyroidism by administering thyroxine and iodine. We had 4 cases of biochemical FT4 elevation during RT too, albeit without any symptoms. In an older paper, Bantle *et al.* also reported no protective effect of thyroxine administered during RT [19]. There were many differences between their study and ours, however, the sample was even smaller than ours; thyroxine medication was begun closer to starting RT; TSH was judged as “suppressed” at higher levels; and the follow-up was less than 3 years. The population of patients with medulloblastoma/PNET considered in our paper did not show indeed a statistical difference in hypothyroidism-free-survival between the two cohorts of patients when updated after 20 years, but this was probably due to the dimension of the sample being reduced from the 36 original patients to the current 22 [3].

As van Santen *et al.* found too (albeit in an animal model) [18], preventing post-RT hypothyroidism did not prevent the occurrence of parenchymal alterations (nodules or colloidal cysts) in our sample.

Radiation-induced thyroid damage varies from one individual to another, with a complex pathogenesis. It evolves very slowly from loss of follicular epithelium function to endothelial changes with cell degeneration and necrosis, thrombosis, acute and chronic inflammation, fibrous organization and partial epithelial regeneration [20]. So far, nobody has succeeded in protecting the thyroid against parenchymal alterations [21,22]. A prolonged TSH suppression after completing RT might be therefore worth trying in a bigger population than the one we treated, also given the absence of significant side effects in our experience.

Harris *et al.* described an invasive procedure involving thyroid transfer to the patient’s forearm before administering RT for adult head and neck tumors: at an initial follow-up of one year, the procedure was successful in all 9 patients treated [23]. The feasibility of this procedure in children remains to be seen.

Our study has several limitations because it involved only a few patients and their number diminished along time. The results came moreover after a not-randomized variable thyroxine intake, due to non-compliance of some

patients and/or not adequate monitoring of their thyroid function, and not to a treatment arm assignment as in a regular trial designed to show one treatment arm superiority. This of course reduces the power of the findings.

This study suggests, however, that hypothyroidism could be easily, cheaply, and durably prevented in two populations at high risk of late effects of RT. Our results need to be confirmed in larger samples, with a true randomized approach and accurately monitoring patients’ TSH levels during a long follow-up.

Acknowledgments

This research received a Grant by AIRC (Associazione Italiana per la Ricerca sul Cancro) in 1998.

Compliance with ethics guidelines

Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, and Monica Terenziani have no conflicts of interest to disclose. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the *Helsinki declaration* of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

References

1. Waguespack SG. Thyroid sequelae of pediatric cancer therapy. *Horm Res Paediatr* 2019; 91(2): 104–117
2. Inskip PD, Veiga LHS, Brenner AV, Sigurdson AJ, Ostroumova E, Chow EJ, Stovall M, Smith SA, Weathers RE, Leisenring W, Robison LL, Armstrong GT, Sklar CA, Lubin JH. Hypothyroidism after radiation therapy for childhood cancer: a report from the Childhood Cancer Survivor Study. *Radiat Res* 2018; 190(2): 117–132
3. Massimino M, Gandola L, Collini P, Seregni E, Marchianò A, Serra A, Pignoli E, Spreafico F, Pallotti F, Terenziani M, Biassoni V, Bombardieri E, Fossati-Bellani F. Thyroid-stimulating hormone suppression for protection against hypothyroidism due to craniospinal irradiation for childhood medulloblastoma/primitive neuroectodermal tumor. *Int J Radiat Oncol Biol Phys* 2007; 69(2): 404–410
4. Massimino M, Gandola L, Pignoli E, Seregni E, Marchianò A, Pecori E, Catania S, Cefalo G. TSH suppression as a possible means of protection against hypothyroidism after irradiation for childhood Hodgkins lymphoma. *Pediatr Blood Cancer* 2011; 57(1): 166–168
5. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* 2016; 131(6): 803–820
6. Wémeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary

- thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. *J Clin Endocrinol Metab* 2002; 87(11): 4928–4934
7. Biondi B, Cooper DS. Thyroid hormone suppression therapy. *Endocrinol Metab Clin North Am* 2019; 48(1): 227–237
 8. Massimino M, Gandola L, Mattavelli F, Pizzi N, Seregni E, Pallotti F, Spreafico F, Marchianò A, Terenziani M, Cefalo G, Biassoni V, Meazza C, Treccate G, Collini P. Radiation-induced thyroid changes: a retrospective and a prospective view. *Eur J Cancer* 2009; 45(14): 2546–2551
 9. Green DM, Brecher ML, Yakar D, Blumenson LE, Lindsay AN, Voorhies ML, MacGillivray M, Freeman AI. Thyroid function in pediatric patients after neck irradiation for Hodgkin disease. *Med Pediatr Oncol* 1980; 8(2): 127–136
 10. Ogilvy-Stuart AL, Shalet SM, Gattamaneni HR. Thyroid function after treatment of brain tumors in children. *J Pediatr* 1991; 119(5): 733–737
 11. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin's disease. *N Engl J Med* 1991; 325(9): 599–605
 12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. *J Am Stat Assoc* 1958; 53(282): 457–481
 13. Miller R, Siegmund D. Maximally selected chi-square statistics. *Biometrics* 1982; 38(4): 1101–1106
 14. Hancock SL, McDougall IR, Constine LS. Thyroid abnormalities after therapeutic external radiation. *Int J Radiat Oncol Biol Phys* 1995; 31(5): 1165–1170
 15. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res* 2012; 178(2): AV43–AV60
 16. Clausen Clausen CT, Hasle H, Holmqvist AS, Madanat-Harjuoja L, Tryggvadottir L, Wesenberg F, Bautz A, Winther JF, de Fine Licht S. Hyperthyroidism as a late effect in childhood cancer survivors — an adult life after childhood cancer in Scandinavia (ALiCCS) study. *Acta Oncol* 2019; 58(2): 227–231
 17. Clement SC, Kremer LCM, Verburg FA, Simmons JH, Goldfarb M, Peeters RP, Alexander EK, Bardi E, Brignardello E, Constine LS, Dinuer CA, Drozd VM, Felicetti F, Frey E, Heinzel A, van den Heuvel-Eibrink MM, Huang SA, Links TP, Lorenz K, Mulder RL, Neggers SJ, Nieveen van Dijkum EJM, Oeffinger KC, van Rijn RR, Rivkees SA, Ronckers CM, Schneider AB, Skinner R, Wasserman JD, Wynn T, Hudson MM, Nathan PC, van Santen HM. Balancing the benefits and harms of thyroid cancer surveillance in survivors of Childhood, adolescent and young adult cancer: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCareSurFup Consortium. *Cancer Treat Rev* 2018; 63: 28–39
 18. van Santen HM, van Dijk JE, Rodermond H, Vansenne F, Endert E, de Vijlder JJ, Haveman J, Vulsma T. Endocrine intervention during irradiation does not prevent damage to the thyroid gland. *Thyroid* 2006; 16(4): 387–395
 19. Bantle JP, Lee CK, Levitt SH. Thyroxine administration during radiation therapy to the neck does not prevent subsequent thyroid dysfunction. *Int J Radiat Oncol Biol Phys* 1985; 11(11): 1999–2002
 20. Nishiyama K, Tanaka E, Tarui Y, Miyauchi K, Okagawa K. A prospective analysis of subacute thyroid dysfunction after neck irradiation. *Int J Radiat Oncol Biol Phys* 1996; 34(2): 439–444
 21. Bhatti P, Veiga LH, Ronckers CM, Sigurdson AJ, Stovall M, Smith SA, Weathers R, Leisenring W, Mertens AC, Hammond S, Friedman DL, Neglia JP, Meadows AT, Donaldson SS, Sklar CA, Robison LL, Inskip PD. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. *Radiat Res* 2010; 174(6): 741–752
 22. Wijnen M, van den Heuvel-Eibrink MM, Medici M, Peeters RP, van der Lely AJ, Neggers SJ. Risk factors for subsequent endocrine-related cancer in childhood cancer survivors. *Endocr Relat Cancer* 2016; 23(6): R299–R321
 23. Harris J, Barber B, Almarzouki H, Scrimger R, Romney J, O'Connell D, Urken M, Seikaly H. Free thyroid transfer: short-term results of a novel procedure to prevent post-radiation hypothyroidism. *Head Neck* 2017; 39(6): 1234–1238